CervoMed posts investor presentation disclosure; info added to websiteTradingView·Oct 14, 2026 at 08:13 PMCRVO+1.34%
CervoMed reports initial 12-week NfL decline in Phase 2a nfvPPA trial; 24-week data due NovTradingView·Oct 13, 2026 at 12:43 PMCRVO+1.34%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Oct 12, 2026 at 05:05 PMAPLM+1.63%CLGN0.00%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Oct 12, 2026 at 12:05 PMCRVO+1.34%CTNM-1.97%
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 | CRVO Stock NewsStockTitan·Oct 12, 2026 at 03:30 AMCRVO+1.34%
FDA Breaks Logjam for Brain Drug, Nine Overlooked Stocks Signal ShiftGlobal Report·Oct 7, 2026 at 10:13 AMYYAI-3.02%BDRY+0.52%
Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed StockSimplywall·Oct 1, 2026 at 11:03 AMCRVO+1.34%
CervoMed Advances Neflamapimod Tablet and Dosing StrategyTip Ranks·Sep 28, 2026 at 09:26 PMCRVO+1.34%
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target ReiteratedTip Ranks·Sep 28, 2026 at 02:45 PMCRVO+1.34%
CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trialsPUBT·Sep 28, 2026 at 11:32 AMCRVO+1.34%
